[18F]-FDG-PET in therapy response of esophageal cancer;18F-FDG-PET zur therapieverlaufskontrolle beim ösophaguskarzinom

Radiologe

Volumn 47, Issue 2, 2007, Pages 110-114

  Wieder, H A ^a   Herrmann, K ^b   Ott, K ^b   Krause, B J ^b  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Esophageal cancer; FDG PET; Therapy response

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; ESOPHAGUS CANCER; EVALUATION; FIBROSIS; HUMAN; PATIENT ASSESSMENT; POSITRON EMISSION TOMOGRAPHY; PREDICTION; QUANTITATIVE ANALYSIS; TREATMENT RESPONSE; TUMOR DIFFERENTIATION;

ESOPHAGEAL NEOPLASMS; FLUORODEOXYGLUCOSE F18; HUMANS; OUTCOME ASSESSMENT (HEALTH CARE); POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RADIOPHARMACEUTICALS; TREATMENT OUTCOME;

EID: 33847204031     PISSN: 0033832X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00117-006-1461-9     Document Type: Article

References (19)

1. Brucher BL, Weber W, Bauer M et al. (2001) Neoadjuvant therapy of esophageal squamous cell carcinoma: response evaluation by positron emission tomography. Ann Surg 233: 300-309
2. Downey RJ, Akhurst T, Ilson D et al. (2003) Whole body 18FDG-PET and the response of esophageal cancer to induction therapy: results of a prospective trial. J Clin Oncol 21: 428-432
3. Flamen P, Van Cutsem E, Lerut A et al. (2002) Positron emission tomography for assessment of the response to induction radiochemotherapy in locally advanced oesophageal cancer. Ann Oncol 13: 361-368
4. Higashi K, Clavo AC, Wahl RL (1993) Does FDG uptake measure proliferative activity of human cancer cells? In vitro comparison with DNA flow cytometry and tritiated thymidine uptake [see comments]. J Nucl Med 34: 414-419
5. Higashi K, Clavo AC, Wahl RL (1993) In vitro assessment of 2-fluoro-2-deoxy-D-glucose, L-methionine and thymidine as agents to monitor the early response of a human adenocarcinoma cell line to radiotherapy [see comments]. J Nucl Med 34: 773-779
6. Jones DR, Parker LA jr, Detterbeck FC, Egan TM (1999) Inadequacy of computed tomography in assessing patients with esophageal carcinoma after induction chemoradiotherapy. Cancer 85: 1026-1032
7. Jones T (1996) The imaging science of positron emission tomography. Eur J Nucl Med 23: 807-813
8. Kelsen DP, Ginsberg R, Pajak TF et al. (1998) Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med 339: 1979-1984
9. Law S, Fok M, Chow S et al. (1997) Preoperative chemotherapy versus surgical therapy alone for squamous cell carcinoma of the esophagus: a prospective randomized trial [see comments]. J Thorac Cardiovasc Surg 114: 210-217
10. Lordick F, Weber WA, Stein HJ et al. (2004) Individualized neoadjuvant treatment strategy in adenocarcinoma of the esophago-gastric junction (AEG): Interim report on the MUNICON trial. J Clin Oncol 22: 4060
11. Ott K, Weber W, Lordick F, et al. (2006) Final results of a prospective trial: metabolic imaging predicts response, survival and recurrence in adenocarcinomas of the esophagogastric junction (AEG). J Clin Oncol, in press
12. Swisher SG, Erasmus J, Maish M et al. (2004) 2-Fluoro-2-deoxy-D-glucose positron emission tomography imaging is predictive of pathologic response and survival after preoperative chemoradiation in patients with esophageal carcinoma. Cancer 101: 1776-1785
13. Swisher SG, Maish M, Erasmus JJ et al. (2004) Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer. Ann Thorac Surg 78: 1152-1160; discussion 1152-1160
14. Warburg O (1930) The metabolism of tumors. Constable, London
15. Weber WA, Ott K, Becker K et al. (2001) Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol 19: 3058-3065
16. Weber WA, Ziegler SI, Thodtmann R et al. (1999) Reproducibility of metabolic measurements in malignant tumors using FDG PET. J Nucl Med 40: 1771-1777
17. Wieder HA, Brucher BL, Zimmermann F et al. (2004) Time course of tumor metabolic activity during chemoradiotherapy of esophageal squamous cell carcinoma and response to treatment. J Clin Oncol 22: 900-908
18. Zuccaro G jr, Rice TW, Goldblum J (1999) Endoscopic ultrasound cannot determine suitability for esophagectomy after aggressive chemoradiotherapy for esophageal cancer. Am J Gastroenterol 94: 906-912
19. Westerterp M, van Westreenen HL, Reitsma JB et al. (2005) Esophageal cancer: CT, endoscopic US, and FDG PET for assessment of response to neoadjuvant therapy - systematic review. Radiology 236: 841-851